Matthew Galsky
马修·加尔斯基
MD
Professor of Medicine and Director, Genitourinary Medical Oncology医学教授兼泌尿生殖肿瘤内科主任
👥Biography 个人简介
Matthew Galsky is a preeminent bladder cancer researcher at Mount Sinai, internationally recognized for leading immunotherapy combination trials and cisplatin-ineligibility research. His work has shaped treatment guidelines for urothelial carcinoma worldwide.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Cisplatin-Ineligibility Criteria
Developed widely adopted consensus criteria defining cisplatin-ineligible bladder cancer patients, enabling appropriate patient selection for clinical trials and immunotherapy regimens.
Neoadjuvant Immunotherapy
Led trials evaluating pembrolizumab and nivolumab in the neoadjuvant setting, demonstrating pathologic complete responses and opening new perioperative treatment strategies.
Representative Works 代表性著作
Gemcitabine-Cisplatin Plus Ipilimumab as First-Line Therapy for Metastatic Urothelial Carcinoma
Journal of Clinical Oncology (2018)
Established safety profile and preliminary efficacy of combined chemo-immunotherapy in urothelial carcinoma.
Defining Cisplatin Ineligibility in Patients with Bladder Cancer
Lancet Oncology (2011)
Landmark consensus paper providing universally applied criteria for cisplatin-ineligible bladder cancer populations.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 马修·加尔斯基 的研究动态
Follow Matthew Galsky's research updates
留下邮箱，当我们发布与 Matthew Galsky（Icahn School of Medicine at Mount Sinai）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment